NEW YORK, November 8, 2016 /PRNewswire/ --
Today is not only a politically important day for the United States, but also a very crucial
day for marijuana industries, as many states will hold referendums on the decision to legalize recreational and medical marijuana
or not. It is estimated that roughly 30 percent of the US population in nine of the states will partake in the vote for the
historical decision. ChineseInvestors.com, Inc. (OTC: CIIX), Medicine Man Technologies, Inc. (OTC: MDCL), Cannabics
Pharmaceuticals Inc. (OTC: CNBX), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY).
According to a report by New Frontier and ArcView Market Research, the regulated cannabis market in the United States is projected to reach more than $7 billion this year. With
many states voting today, all eyes will be focused on the Legalization of Cannabis.
Last week, ChineseInvestors.com Inc. (OTCQB: CIIX), announced that it will launch the world's first Chinese-language
subscriber-only information service specifically focused on emerging growth companies in the Cannabis sector. The content of this
service will cover the medical and recreational cannabis markets, the latest trends and technologies in the industry, and any
investment opportunities in either private or publicly traded cannabis companies. The subscription service is expected to be
launched after January 1st, 2017.
Just today ChineseInvestors.com Inc. announces that it will launch the world's first Chinese-language talk show specifically
focused on investment opportunities in the Cannabis sector. The content of this talk show will follow the latest trends in both
the medical and recreational cannabis markets, explore the promising growth of this new emerging industry, and identify select
cannabis equities with the greatest potential for capital appreciation. The five-minute talk show is expected to be launched
after December 1st, 2016, and it will be available on the company's official Youtube
Channel as well as the Phoenix North America Chinese Channel, which is one of the most popular subscriber-only media platforms in
the Chinese-speaking communities.
Warren Wang, founder and CEO of Chineseinvestors.com, commented: "Many Chinese investors still
have a bias against the cultivation and sales of cannabis and we need to make them aware of the huge potential business
opportunities within this industry. In addition, if recreational marijuana is legalized in California, an estimated $1 billion in new tax revenue would be directed
toward specific drug use prevention programs and treatment, helping at-risk youth, law enforcement, and medical cannabis
research…In 2015, 1.8 million Chinese tourists visited United States. We believe that many of
these tourists may be curious about the California cannabis legislation and may come to the
state to either experience the American recreational marijuana culture or invest in this emerging market. Our plan to launch a
first of its kind Chinese-language talk show focused specifically on the cannabis sector will definitely assist the
Chinese-speaking investor in overcoming the language barrier and also help cannabis retailers to attract more potential medical
users."
ChineseInvestors.com Inc. saw a great opportunity to enter the cannabis sector and holds or held a stake with consulting
service company that covers all aspects of cannabis cultivation, Medicine Man Technologies, Inc. (OTCQB: MDCL). The
company implemented a risk averse growing environment, applying high-tech indoor cannabis cultivation equipment and works in
medical and adult use dispensaries. Medicine Man Technologies assisted Illinois and Nevada licensees to organize these practices after acquiring cultivation and dispensary operational
licenses. Currently, the company has reinforced competitive application filings in Maryland and
Hawaii and has pre-licensure clients in Texas, California, Florida, Ohio, Arkansas, and Oklahoma and has engaged potential clients in Alaska, Delaware, Utah, Michigan, Nebraska, Puerto Rico, and
abroad.
Cannabics Pharmaceuticals Inc. (OTC: CNBX) announced results from the company's latest cancer HTS research overtly
conclude that, depending upon the THC/CBD ratio, specific Cannabis extracts are directly contributive to reducing U87MG
glioblastoma cell viability. "The Cannabics' method of diagnosis clearly differentiates between a multitude of varied plant
extracts and their apoptotic and necrotic effects by utilizing state of the art of High Through-put Screening on cells derived
from patients' biopsies; the results of which are visualized in "scans" of the before, during and after effect upon the cancer
cells themselves" said Chief Scientist of Cannabics Pharmaceuticals, Dr. Eyal Ballan.
Biotechnology Company, Cara Therapeutics Inc. (NASDAQ: CARA), is pleased to be actively enrolling late stage studies
with both IV and oral formulations of CR845 for three significant unmet medical indications. In September
2016, Cara initiated the enrollment of a Phase 2b trial of Oral CR845 in roughly 330 patients for the treatment of pain
associated with osteoarthritis and presented positive data at PAINWeek from the Phase 2a study of Oral CR845 in OA. In October,
company initiated Phase 1 study with Oral CR845 in hemodialysis patients.
Chairman, President and Chief Executive Officer of Insys Therapeutics Inc. (NASDAQ: INSY), Dr. John N. Kapoor has commented on the company's recent third quarter 2016 noting that Subsys volumes declined in
the quarter, and is pleased to have maintained a mid-40 percent market share and believe the product will continue to provide a
solid financial foundation for growth and to support the company's R&D efforts. The company is anticipating Drug Enforcement
Administration scheduling of Syndros, it's recently FDA approved product for the treatment of cancer induced nausea and vomiting
and anorexia related with weight loss in AIDS patients. INSY is excited about their main pipeline and believe that both its spray
and cannabinoid platform products will provide opportunities for future growth.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
For "The Latest Buzz in Financial News", SIGN UP & Visit: http://www.FinancialBuzz.com
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and
advertising for third parties for disseminating news and original content through our unique media platform that includes
Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and pr marketing firm enters into
service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies.
Financialbuzz.com has not been compensated for financial news dissemination and pr services by any company mentioned in our
sophiscated article. We are not an independent news media provider and therefore do not represent or warrant that the information
posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality
and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum
or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly
paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the
engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information
about any companies the information contained herein is not intended to be used as the basis for investment decisions and should
not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to
buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result
from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended
from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase,
hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor.
This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular
security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and
tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to
change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact: info@financialbuzz.com , +1-877-601-1879
SOURCE FinancialBuzz.com